XML 45 R25.htm IDEA: XBRL DOCUMENT v3.20.1
NewLink Genetics Merger (Details)
3 Months Ended
Mar. 19, 2020
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Mar. 18, 2020
USD ($)
Feb. 04, 2020
Dec. 31, 2015
USD ($)
Business Acquisition [Line Items]            
In-process research and development charge   $ 426,000 $ 0      
Private Lumos Stockholders | NewLink Genetics            
Business Acquisition [Line Items]            
Ownership percentage after transaction 0.50          
Merck, Sharpe and Dohme Corp | License and Collaborative Arrangement            
Business Acquisition [Line Items]            
Value of PRV company is entitled to       60.00% 60.00%  
Value of PRV liability       40.00%    
Estimated transaction price       $ 95,000,000.0    
Merck, Sharpe and Dohme Corp | License and Collaborative Arrangement | Minimum            
Business Acquisition [Line Items]            
Observed transaction price       80,000,000.0    
Merck, Sharpe and Dohme Corp | License and Collaborative Arrangement | Maximum            
Business Acquisition [Line Items]            
Observed transaction price       111,000,000.0   $ 350,000,000.0
NewLink Genetics            
Business Acquisition [Line Items]            
Cash and cash equivalents       84,179,000    
Prepaid and other current assets       2,999,000    
Income tax receivable       192,000    
Property and equipment       1,020,000    
Economic interest in PRV       87,920,000    
Other intangible assets       426,000    
Other non-current assets       517,000    
Total Assets Acquired       177,253,000    
Accounts payable       285,000    
Accrued expenses and other current liabilities       8,788,000    
PRV-related liability owed to Merck       35,720,000    
Royalty obligation payable to Iowa Economics Development Authority       6,000,000    
Deferred tax liability       9,500,000    
Other long-term liabilities       12,000    
Total liabilities assumed       60,305,000    
Total net assets acquired       $ 116,948,000